Sinemet CR^® improves the signs of Parkinson’s. 

Sinemet CR^® contains two different medicines called: levodopa and carbidopa:

• levodopa turns into a material called ‘dopamine’ in your brain. The dopamine helps to improve the signs of your Parkinson’s.
• carbidopa belongs to a group of medicines called ‘aromatic amino aciddecarboxylase inhibitors’. It helps levodopa work more effectively by slowing the speed at which levodopa is broken down in your body.

Patient Information Leaflet (PIL) and Summary of Product Characteristics (SPC)

The PIL is the leaflet that is included with a medicine and is a patient-friendly version of the Summary of Product Characteristics. It gives information about taking or using a medicine. 

The SPC is used by healthcare professionals and explains how to use and prescribe a medicine.

The following link provides detailed, up-to-date information on the various available forms of Sinemet^®, their handling and use. As information leaflets are approved by the regulatory body in each country in which a medication is licensed – and are therefore too numerous to list – we have given only the UK example. This link goes to the Electronic Medicines Compendium (eMC) website.

• https://www.medicines.org.uk/emc/search?q=sinemet

Madopar^® capsules contain two medicines called levodopa and benserazide. They are used to treat Parkinson’s.

People with Parkinson’s disease do not have enough dopamine in certain parts of their brains. This can result in slow movements, stiff muscles and tremor. Madopar^® works as follows:

• In your body the levodopa is changed into dopamine. Dopamine is the active medicine that is needed in your brain to help Parkinson’s
• The benserazide allows more of the levodopa you take to get into your brain, before it is changed into dopamine. 

Patient Information Leaflet (PIL) and Summary of Product Characteristics (SPC)

The PIL is the leaflet that is included with a medicine and is a patient-friendly version of the Summary of Product Characteristics. It gives information about taking or using a medicine.

The SPC is used by healthcare professionals and explains how to use and prescribe a medicine.

The following link provides detailed, up-to-date information on the various available forms of Madopar^®, their handling and use. As information leaflets are approved by the regulatory body in each country in which a medication is licensed – and are therefore too numerous to list – we have given only the UK example. This link goes to the Electronic Medicines Compendium (eMC) website.

• https://www.medicines.org.uk/emc/search?q=madopar

Stalevo^® contains three active substances (levodopa, carbidopa and entacapone) in one film-coated tablet. Stalevo^® is used for the treatment of Parkinson’s.

Parkinson’s is caused by low levels of a substance called dopamine in the brain. Levodopa increases the amount of dopamine and therefore reduces the symptoms of Parkinson’s. Carbidopa and entacapone improve the antiparkinson effects of levodopa.

Patient Information Leaflet (PIL) and Summary of Product Characteristics (SPC)

The PIL is the leaflet that is included with a medicine and is a patient-friendly version of the Summary of Product Characteristics. It gives information about taking or using a medicine.

The SPC is used by healthcare professionals and explains how to use and prescribe a medicine.

The following link provides detailed, up-to-date information on the various available forms of Stalevo^®, their handling and use. As information leaflets are approved by the regulatory body in each country in which a medication is licensed – and are therefore too numerous to list – we have given only the UK example. This link goes to the Electronic Medicines Compendium (eMC) website.

• https://www.medicines.org.uk/emc/search?q=stalevo

European Public Assessment Report (EPAR)

EPARs are full scientific assessment reports of medicines authorised at a European Union level.

Links below go to the European Medicines Agency (EMA) website. The European Medicines Agency is a decentralised agency of the European Union, located in London. The Agency is responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in the European Union.

The EMA publishes an EPAR for every medicine granted a central marketing authorisation by the European Commission following an assessment by the EMA's Committee for Medicinal Products for Human Use (CHMP). EPARs are full scientific assessment reports of medicines authorised at a European Union level.

• Stalevo^® European Public Assessment Report (EPAR) - Read report

Lecado^® is a combination of carbidopa (an aromatic amino acid decarboxylase inhibitor) and levodopa (the metabolic precursor of dopamine) in the form of a prolonged-release tablet on a polymer base for treating Parkinson's.

Lecado^® is particularly useful in reducing “off” period in people previously treated with the immediate-release levodopa/decarboxylase inhibitor combination who have also had dyskinesia and motor fluctuations.

Summary of Product Characteristics (SPC)

The SPC is used by healthcare professionals and explains how to use and prescribe a medicine.

As information leaflets are approved by the regulatory body in each country in which a medication is licensed – and are therefore too numerous to list – we have given only the UK example. This link goes to the Electronic Medicines Compendium (eMC) website.

• https://www.medicines.org.uk/emc/search?q=lecado

Duodopa^® belongs to a group of medicines for the treatment of Parkinson’s and contains two medicines in a gel: levodopa and carbidopa monohydrate.

Levodopa is made into dopamine in the body. Dopamine is present in your brain and in your spinal cord. It helps transfer signals between nerve cells. Too little dopamine causes Parkinson’s disease signs such as tremor, feeling rigid, slow movements, and problems keeping your balance. Treatment with levodopa increases the amount of dopamine in your body and so reduces these signs. Carbidopa monohydrate is added to improve the effect and reduce the undesirable effects of levodopa.

Patient Information Leaflet (PIL) and Summary of Product Characteristics (SPC)

The PIL is the leaflet that is included with a medicine and is a patient-friendly version of the Summary of Product Characteristics. It gives information about taking or using a medicine.

The SPC is used by healthcare professionals and explains how to use and prescribe a medicine.

The following link provides detailed, up-to-date information on the various available forms of Duodopa^®, their handling and use. As information leaflets are approved by the regulatory body in each country in which a medication is licensed – and are therefore too numerous to list – we have given only the UK example. This link goes to the Electronic Medicines Compendium (eMC) website.

• https://www.medicines.org.uk/emc/product/6231